Olaparib an anticancer drug: A review

  • Rohit Deepak Nalawade
  • Bhagwan Dilip Devkar
N/ACitations
Citations of this article
11Readers
Mendeley users who have this article in their library.

Abstract

Olaparib is an anti-cancer drug which comes under N-acyl piperazines class. The action of olaparib is PRPA inhibition. Drug taken by oral route which shows action in 1 to 3 hrs. after administration. It is FDA approved drug for various cancer treatment such as ovarian cancer, breast cancer, prostatic cancer and pancreatic cancer. Olaparib also useful different mutation conditions such as BRCA1/2 mutation. Olaparib prescribes after the chemotherapy treatment either singly or in combination. In serious and advanced mutation conditions combination therapy used. In this review paper, we put a narrative information about olaparib action, treatment approaches, pharmacokinetics, dosing regimen and resistance. Here we briefly give information about resistance mechanism of olaparib, treatment approaches in ovarian cancer, breast cancer and prostate cancer.

Cite

CITATION STYLE

APA

Rohit Deepak Nalawade, & Bhagwan Dilip Devkar. (2021). Olaparib an anticancer drug: A review. World Journal of Advanced Research and Reviews, 11(2), 329–336. https://doi.org/10.30574/wjarr.2021.11.2.0406

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free